TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Prediction and Prevention of Asymptomatic Cardiovascular Insult in Type 1 Diabetic Children: Comparative Effectiveness of Cardioprotective Drugs

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Children and adolescent suffering from type 1 Diabetes Mellitus, for at least 3 years from the onset of the disease.~Exclusion Criteria:~* Children with Congenital Heart Diseases.~* Children with acquired cardiac diseases.~* Children with other systemic diseases.~* Symptomatic diabetic cardiomyopathy.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- diabetic- no cardioprotectives (Type: NO_INTERVENTION): 25 child with type 1 diabetes mellitus will not receive any cardio protective drug
- diabetic-Atorvastatin (Type: EXPERIMENTAL): 25 child with type 1 diabetes mellitus will receive Statin (2 mg/kg/day)
- diabetic-Captopril (Type: EXPERIMENTAL): 25 child with type 1 diabetes mellitus will receive Captopril (0.2 mg/kg/day)
- diabetic-L-Carnitine (Type: EXPERIMENTAL): 25 child with type 1 diabetes mellitus will receive L-carnitine (50 mg/kg/day)
- Controls (Type: NO_INTERVENTION): 50 healthy children, of matched age and sex, with no symptoms of cardiac diseases

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Study of Fluoxetine in Children and Adolescents With Autism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
PROTOCOL ENTRY CRITERIA:~--Disease Characteristics--~Meets diagnostic criteria for autism~--Prior/Concurrent Therapy--~Other:~* At least 3 months since prior electroconvulsive therapy~* At least 1 month since prior investigational drugs or treatment with any drug known to cause major organ toxicity~* At least 2 weeks since prior monoamine oxidase inhibitors~* At least 6 weeks since prior long acting phenothiazines~* At least 1 week since prior other psychotropic drugs~* No prior fluoxetine of 20 mg/day for 6 weeks~* At least 6 weeks since prior fluoxetine~* No concurrent use of terfenadine (Seldane) or astemizole (Hismanal)~* No concurrent electroconvulsive therapy or other psychotropic drugs (unless otherwise permitted)~* Prior participation in another serotonin reuptake inhibitor trial allowed~--Patient Characteristics--~Hematopoietic: No significant hematopoietic disease~Hepatic: No prior or concurrent liver disease~Renal: No prior or concurrent kidney disease~Cardiovascular:~* No significant cardiovascular disease~* No abnormal EKG~Neurological:~* No prior seizure disorder or high risk development of seizures~* No prior cerebrovascular disease~* No prior brain trauma~Other:~* Not pregnant or nursing~* Negative pregnancy test~* No unstable major medical illness or systemic disease~* No moderate or severe mental retardation and motor deficits (IQ less than 50)~* No family history of bipolar disorder~* No prior or concurrent other mental disorders (e.g., schizophrenia, schizoaffective, organic, or bipolar disorders)~* No significant autoaggressive behavior or serious suicidal risk~* No prior or concurrent gastrointestinal conditions~* No unstable endocrine disease (e.g., hypo or hyperthyroidism)~* No prior or concurrent malignancy~* Must be able to tolerate tapering of psychoactive medication~* No history of hypersensitivity or severe side effects to fluoxetine or other serotonin reuptake inhibitors~* No history of severe personality disorder or noncompliance

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Nitazoxanide Suspension in the Treatment of Diarrhea Caused by Enteric Viruses in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \<12 years.~* Patients with diarrhea (defined as 3 or more stools per day with liquid or semi-solid consistency, the number and consistency of stools being unusual for that person).~* Stool positive for adenovirus, norovirus or rotavirus by ELISA.~Exclusion Criteria:~* Females who are pregnant, suspected of being pregnant or breastfeeding.~* Other identified causes of diarrhea at screening.~* Serious systemic disorders incompatible with the study.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Nitazoxanide (Type: ACTIVE_COMPARATOR): 7.5mg/kg (age under 12 months), 5 mL (100mg nitazoxanide; age 1-3 years), 10 mL (200mg nitazoxanide; age 4-11 years) twice daily x 3 days
- Placebo (Type: PLACEBO_COMPARATOR): 7.5mg/kg (age under 12 months), 5 mL (100mg nitazoxanide; age 1-3 years), 10 mL (200mg nitazoxanide; age 4-11 years) twice daily x 3 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Drug Interaction Study of Saxagliptin in Combination With Dapagliflozin in Healthy Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy subjects as determined by no clinically significant deviation from normal in medical history, Physical Examination, vital signs, 12-lead ECG, and clinical laboratory determinations~* Body mass index (BMI) of 18 to 30 kg/m2~* Men and women, ages 18 to 45 years~* Women of childbearing potential must use acceptable methods of highly effective birth control~Exclusion Criteria:~* History of chronic or recurrent urinary tract infection for females~* History of allergies or adverse reactions to Dipeptidyl peptidase-IV (DPP4) or Sodium-glucose transporter type 2 (SGLT2) inhibitors~* Any significant acute or chronic medical illness~* Current or recent gastrointestinal disease~* Any major surgery within 4 weeks of study drug administration~* Prior exposure to saxagliptin or dapagliflozin or related drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- A-B-C: Saxagliptin-Dapagliflozin-(Saxagliptin+Dapagliflozin) (Type: EXPERIMENTAL): Treatment A: Saxagliptin 5mg, Tablet, Oral; Single dose Treatment B: Dapagliflozin 10mg, Tablet, Oral; single dose Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral; single dose
- A-C-B: Saxagliptin-(Saxagliptin+Dapagliflozin)-Dapagliflozin (Type: EXPERIMENTAL): Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose; Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose; Treatment B: Dapagliflozin 10mg, Tablet, Oral, single dose
- B-A-C: Dapagliflozin-Saxagliptin-(Saxagliptin+Dapagliflozin) (Type: EXPERIMENTAL): Treatment B: Dapagliflozin 10mg, Tablet, Oral, single dose. Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose; Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose
- B-C-A: Dapagliflozin-(Saxagliptin+Dapagliflozin)-Saxagliptin (Type: EXPERIMENTAL): Treatment B: Dapagliflozin 10mg, Tablet, Oral, single dose; Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose; Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose
- C-A-B: (Saxagliptin+Dapagliflozin)-Saxagliptin-Dapagliflozin (Type: EXPERIMENTAL): Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose; Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose; Treatment B: Dapagliflozin 10mg, Tablet, Oral, single dose
- C-B-A: (Saxagliptin+Dapagliflozin)-Dapagliflozin-Saxagliptin (Type: EXPERIMENTAL): Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose; Treatment B: Dapagliflozin 10mg, Tablet, Oral, Once daily, single dose; Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Subject Reported Outcomes With Use of Adapalene 0.3% - Benzoyl Peroxide (BPO) 2.5% in Dark Skin Acne

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject with clinical diagnosis of moderate to severe facial acne vulgaris, defined by:~  1. Investigator's Global Assessment (IGA) score of 3 (Moderate) OR 4 (Severe ); and~ 2. A minimum of 25-100 inflammatory lesions (papules and pustules); and~ 3. A minimum of 30-150 non-inflammatory lesions (open and closed comedones) in total (excluding the nose); and~ 4. No more than two acne nodules (≥ 1 cm),~* Subject with skin phototype IV to VI on Fitzpatrick skin phototype scale,~* Subjects from one of the 3 ethnic/race backgrounds: Asian, Latin American and Black/African-American,~Exclusion Criteria:~* Subject with acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne, etc.), nodulo cystic acne, acne requiring systemic treatment,~* Subject with history of lupus, atopic dermatitis, perioral dermatitis, dermatomyositis, rosacea~* Female subject who is pregnant, lactating or planning a pregnancy during the trial,~* Subjects having received at least one of the following topical treatments on the treated area: Corticosteroids, antibiotics, benzoyl peroxide, azelaic acid, dapsone, hydroxyacids, Zinc containing treatments, antiseptics, other anti-inflammatory products or other acne treatments (2 weeks); Retinoids (4 weeks); Cosmetic/aesthetic procedures on the face (1 week); Wax epilation (2 weeks); Photodynamic therapy (6 weeks); Laser therapy, microdermabrasion, deep chemical peel, plastic surgery for acne (3 months).~* Subjects having received at least one of the following systemic treatments: Corticosteroids, tetracyclines, other antibiotics (except penicillin) (1 month); Oral retinoids/isotretinoin/ anti-androgens / Cyproterone acetate / Chlormadinone acetate (6 months); Spironolactone/ Drospirenone (3 months); Immunomodulators (3 months) and Oral contraceptives/ oral dapsone for acne(1 month).

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adapalene / BPO gel (Type: EXPERIMENTAL): Adapalene 0.3% / BPO 2.5% gel, once daily in the evening

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: EArly Discharge After Transradial Stenting of CoronarY Arteries: The EASY Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with documented ischemic coronary artery disease and scheduled for possible coronary artery stenting are eligible.~* Patient must be \> 18 years of age.~* Patient and treating interventional cardiologist agree for randomization.~* Patient will be informed of the randomization process and will sign an informed consent.~* Diagnostic and therapeutic intervention performed through trans-radial/ulnar artery approach.~Exclusion Criteria:~CLINICAL:~* Patients with recent (\< 72 hrs) Q-wave (ST elevation) acute myocardial infarction.~* History of LV ejection fraction ≤ 30%.~* Unstable clinical condition.~* Any complication compromising ambulation~* Concurrent participation in other investigational study requiring prolonged hospitalization~* Required prolonged hospitalization~* In-cath lab transient vessel closure~* Resuscitation per PCI~* Hemodynamic collapse during PCI~* Severe entry site complication upon investigator decision~* Social isolation~* Serious cognitive disorders~* Femoral sheath (artery)~* Persisting chest pain~* No ASA prior PCI~* Allergy to ASA or thienopyridines precluding treatment for 30 days~* Any significant blood dyscrasia~* PCI without stent implantation (except for bifurcation lesion or re-dilatation for in-stent restenosis)~* International Normalised Ratio (INR) \> 2.0~* Contraindication to Reopro administration~ANGIOGRAPHIC~* Residual dissection of grade ≥ B of NHBLI classification.~* Compromised or sub-occluded branch with diameter ≥ 1 mm.~* Timi \< 3 post-stenting~* Thrombus post-PCI

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial to Evaluate Efficacy and Safety of SID142 in Patients With Chronic Artery Occlusive Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or Female outpatients over 20years of age~2. patients confirmed to have PAD~   * ABI ≤0.9~  * Occlusion rate\>50%~3. LE PAD with Fontaine stage II/III~4. LE pain VAS≥40mm at screening~Exclusion Criteria:~1. Patients who underwent vascular surgery or endovascular procedure for PAD within 1month prior to study. Patients who need vascular surgery or endovascular procedure for PAD during this study also should be excluded.~2. Patients with peripheral neuropathy.~3. Patients with ischemic heart diseases or underwent percutaneous transluminal coronary angioplasty or coronary artery bypass graft within 6 months prior to study.~4. Patients who has diagnosed cerebrovascular diseases within 6 months prior to study.~5. Patients with hemorrhage or predisposition to hemorrhage at screening visit.~6. Uncontrolled hypertension defined as ≥ 180 mmHg of systolic blood pressure or ≥ 110 mmHg of diastolic blood pressure

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SID142 (Type: EXPERIMENTAL): Patients administrate SID142 (Cilostazol 200mg, Ginkgo biloba leaf extract 160mg) once a day for 12 weeks
- Rinexin® Tab (Type: ACTIVE_COMPARATOR): Patients administrate Rinexin® Tab (Cilostazol 100mg, Ginkgo biloba leaf extract 80mg) twice a day for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pre-emptive Scalp Infiltration With Dexamethasone Plus Ropivacaine for Postoperative Pain After Craniotomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients scheduled for elective craniotomy for resection of a supratentorial tumour under general anaesthesia;~* American Society of Anesthesiologists (ASA) physical status of I or II;~* Participates required to fix their head in a head clamp intraoperatively;~* Participates with an anticipated fully recovery within 2 hours postoperatively.~Exclusion Criteria:~* History of craniotomy;~* Expected delayed extubation or no plan to extubate;~* Participants who cannot use a patient-controlled analgesia (PCA) device;~* Participants who cannot understand the instructions of a numeral rating scale (NRS) 35 before surgery;~* Extreme body mass index (BMI) (\< 15 or \> 35);~* Allergy to opioids, dexamethasone or ropivacaine;~* History of excessive alcohol or drug abuse, chronic opioid use (more than 2 weeks), or use of drugs with confirmed or suspected sedative or analgesic effects;~* History of psychiatric disorders, uncontrolled epilepsy or chronic headache;~* Pregnant or at breastfeeding;~* Symptomatic cardiopulmonary, renal, or liver dysfunction or history of diabetes;~* Preoperative Glasgow Coma Scale\< 15;~* Suspicion of intracranial hypertension;~* Peri-incisional infection;~* Participants who have received radiation therapy and chemotherapy preoperatively or with a high probability to require a postoperative radiation therapy and chemotherapy according to the preoperative imaging.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Dexamethasone plus Ropivacaine group (Type: EXPERIMENTAL): Participates received peri-incisional scalp infiltration of a miscible liquid of dexamethasone and ropivacaine. The local infiltration miscible liquid containing 0.33mg dexamethasone and 5mg ropivacaine per milliliter
- Ropivacaine group (Type: ACTIVE_COMPARATOR): Participates received peri-incisional scalp infiltration of 5mg/mL ropivacaine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Topical Rapamycin to Erase Angiofibromas in TSC

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must be willing and able to comply with all trial requirements.~* Subject has a diagnosis of TSC and has visible facial angiofibromas.~* Female subjects of child bearing potential must not be pregnant and must agree to use appropriate contraceptive methods .~Exclusion Criteria:~* Subject is currently receiving therapy with Rapamycin.~* Subject is receiving any form of immunosuppression or has previously experienced immune dysfunction.~* Subject is currently participating in or has participated within the last 30 days in a clinical trial involving an investigational drug.~* Subject has a known hypersensitivity to either the vehicle or Rapamycin.~* Subject is a pregnant or nursing female.~* Subject has other dermatologic conditions that would preclude or prevent adequate assessment of changes to their facial angiofibromas.~* Subject has had laser surgery, cryotherapy, or other dermatologic treatment to their facial angiofibromas within the previous 6 months.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Cream only
- 0.1 % Rapamycin (Type: ACTIVE_COMPARATOR): 0.1% Rapamycin cream
- 1% Rapamycin (Type: ACTIVE_COMPARATOR): 1% Rapamycin cream

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility Study of a Web-based Program to Help Parents of Middle School Students Effectively Communicate With Their Children About Substance Use

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The adult must be the legal guardian of a child in 6th, 7th or 8th grade (known hereafter as parent).~* The parent must be able and willing to receive email and text communication as part of the study.~* The parent-child pair must have access to a smartphone with internet connection as the resource review will be completed online in a format that is best viewed on a smartphone.~* The parent-child pair must be fluent in English as the study materials are conducted in English.~* The parent must indicate that they will give the child participant privacy to complete the questionnaires~* Both the adult and child must agree to participate.~Exclusion Criteria:~* In an effort to ensure diversity in parent gender and race/ethnicity, not all eligible pairs who are interested in participating will be enrolled in the study.

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Web-based intervention (Type: EXPERIMENTAL): The intervention is a web-based resource that provides parents with media literacy and media mediation skills, knowledge about adolescent development and substance use, and practice in high quality parent-child communication.
- Active Control Program (Type: ACTIVE_COMPARATOR): The active control is a web-based resource that contains PDFs of medically accurate information about adolescent substance use.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PROUD Study: A Prospective Study on the Usage Patterns of Doripenem in the Asia Pacific Region

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients hospitalized either in the ICU or ward, with a diagnosis of pneumonia, complicated abdominal infections, or complicated urinary tract infection using the protocol-defined Guidelines for Diagnosis~Exclusion Criteria:~* Pregnant or lactating females~* Allergies to Doripenem or its derivatives~* Infected by a bacteria that is resistant to Doripenem~* Taking probenecid~* Severe allergies to other antibiotics like penicillins, cephalosporins, or carbapenems~* Severe kidney disease, in an unstable disease state and assessed as unlikely to survive until the study follow up period~* Signs of severe sepsis with treatment failure with other carbapenems, who received other carbapenem within 2 weeks before first dose of study drug, and who has any condition that, in the opinion of the investigator, would compromise the well-being of the patient or the study or prevent the patient from meeting or performing study requirements

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- 001 (Type: OTHER): doripenem 500mg vial by injection every 8 hours for 5 to 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete